The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research At 2024 GPEN Conference Vancouver, British Columbia
Today is a day to honour Dr Daniel Sitar: Fellowship Canadian Society of Pharmacology and
BIOMARK Announces Warrant Extension and Granting of Options Vancouver, British Columbia – (April 18th, 2024)
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding
Vancouver, British Columbia – (February 28, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”)
Vancouver, British Columbia – (February 26, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE:
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia – (December 29th,
BioMark Diagnostics Inc: Innovating Cancer Detection From the interview originally published by insightscare https://insightscare.com/biomark-diagnostics-inc-innovating-cancer-detection/ Rashid
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]